New pill shows promise against fatty liver disease in early trial
NCT ID NCT06168383
First seen Feb 15, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tested an experimental drug called HSK31679 in 186 Chinese adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease with scarring. Participants took either 80 mg, 160 mg, or a placebo daily for 52 weeks. The main goal was to see if the drug could improve liver damage without worsening fibrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tsinghua Changgung Hospital, Tsinghua University
Beijing, China
Conditions
Explore the condition pages connected to this study.